Misplaced Pages

Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.

References

1. Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
2. Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antimalarial agents
• Combination antiviral drugs
• Withdrawn drugs
• Antiinfective agent stubs